A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)
- PMID: 20008785
- DOI: 10.1182/blood-2009-09-245837
A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)
Abstract
Age older than 65 years, hemoglobin level lower than 100 g/L (10 g/dL), white blood cell count greater than 25 x 10(9)/L, peripheral blood blasts 1% or higher, and constitutional symptoms have been shown to predict poor survival in primary myelofibrosis (PMF) at diagnosis. To investigate whether the acquisition of these factors during follow-up predicts survival, we studied 525 PMF patients regularly followed. All 5 variables had a significant impact on survival when analyzed as time-dependent covariates in a multivariate Cox proportional hazard model and were included in 2 separate models, 1 for all patients (Dynamic International Prognostic Scoring System [DIPSS]) and 1 for patients younger than 65 years (age-adjusted DIPSS). Risk factors were assigned score values based on hazard ratios (HRs). Risk categories were low, intermediate-1, intermediate-2, and high in both models. Survival was estimated by the HR. When shifting to the next risk category, the HR was 4.13 for low risk, 4.61 for intermediate-1, and 2.54 for intermediate-2 according to DIPSS; 3.97 for low risk, 2.84 for intermediate-1, and 1.81 for intermediate-2 according to the age-adjusted DIPSS. The novelty of these models is the prognostic assessment of patients with PMF anytime during their clinical course, which may be useful for treatment decision-making.
Similar articles
-
The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation.Blood. 2012 Mar 15;119(11):2657-64. doi: 10.1182/blood-2011-08-372904. Epub 2012 Jan 10. Blood. 2012. PMID: 22234678 Free PMC article.
-
Associations and prognostic interactions between circulating levels of hepcidin, ferritin and inflammatory cytokines in primary myelofibrosis.Am J Hematol. 2013 Apr;88(4):312-6. doi: 10.1002/ajh.23406. Epub 2013 Feb 28. Am J Hematol. 2013. PMID: 23450619
-
DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status.J Clin Oncol. 2011 Feb 1;29(4):392-7. doi: 10.1200/JCO.2010.32.2446. Epub 2010 Dec 13. J Clin Oncol. 2011. PMID: 21149668
-
Primary myelofibrosis: 2017 update on diagnosis, risk-stratification, and management.Am J Hematol. 2016 Dec;91(12):1262-1271. doi: 10.1002/ajh.24592. Am J Hematol. 2016. PMID: 27870387 Review.
-
Primary myelofibrosis: 2012 update on diagnosis, risk stratification, and management.Am J Hematol. 2011 Dec;86(12):1017-26. doi: 10.1002/ajh.22210. Am J Hematol. 2011. PMID: 22086865 Review.
Cited by
-
Upfront allogeneic transplantation versus JAK inhibitor therapy for patients with myelofibrosis: a North American collaborative study.Bone Marrow Transplant. 2024 Feb;59(2):196-202. doi: 10.1038/s41409-023-02146-6. Epub 2023 Nov 8. Bone Marrow Transplant. 2024. PMID: 37938736 Free PMC article.
-
The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation.Blood. 2012 Mar 15;119(11):2657-64. doi: 10.1182/blood-2011-08-372904. Epub 2012 Jan 10. Blood. 2012. PMID: 22234678 Free PMC article.
-
Prognostic and Predictive Models in Myelofibrosis.Curr Hematol Malig Rep. 2024 Oct;19(5):223-235. doi: 10.1007/s11899-024-00739-6. Epub 2024 Aug 24. Curr Hematol Malig Rep. 2024. PMID: 39179882 Free PMC article. Review.
-
Primary myelofibrosis: risk stratification by IPSS identifies patients with poor clinical outcome.Clinics (Sao Paulo). 2013;68(3):339-43. doi: 10.6061/clinics/2013(03)oa09. Clinics (Sao Paulo). 2013. PMID: 23644853 Free PMC article.
-
The role of circulating monocytes and JAK inhibition in the infectious-driven inflammatory response of myelofibrosis.Oncoimmunology. 2020 Jun 23;9(1):1782575. doi: 10.1080/2162402X.2020.1782575. Oncoimmunology. 2020. PMID: 32923146 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical